Janssen’s Ponvory Will Face Stiff Competition In Europe’s MS Market

Janssen Pharmaceutical Cos. (Johnson & Johnson)’s new oral once-daily multiple sclerosis therapy, Ponvory (ponesimod), has been approved for marketing in the EU, where it is expected to carve out a role as a new treatment option, despite the condition benefiting from a slew of new product introductions. 

Like in the US, where ponesimod was approved two months previously, the new sphingosine 1-phosphate (S1P) receptor modulator is entering a busy market segment, which has seen two recent EU approvals for S1P modulators, for Bristol Myers Squibb Company’s Zeposia (ozanimod) and Novartis AG’s Mayzent (siponimod)